Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maarten J Postma

Showing results (171-180 of 485) with videos related to

Pageof 49
Sort By:
Journal of Medical Economics|May 20, 2017
Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the NetherlandsMarieke Heisen, Maarten J Treur, Harald E Heemstra, et al.
Value in Health Regional Issues|February 24, 2018
Health-Related Quality of Life of Patients with HPV-Related Cancers in IndonesiaDidik Setiawan, Arrum Dusafitri, Githa Fungie Galistiani, et al.
Value in Health Regional Issues|January 9, 2024
Analysis of Health-Related Quality of Life and Incurred Costs Among Human Immunodeficiency Virus, Tuberculosis, and Tuberculosis/HIV Coinfected Outpatients in IndonesiaLusiana R Idrus, Najmiatul Fitria, Fredrick D Purba, et al.
Epidemiology (Cambridge, Mass.)|November 1, 2017
Estimating the Population-Level Effectiveness of Vaccination Programs in the NetherlandsMaarten van Wijhe, Scott A McDonald, Hester E de Melker, et al.
Vaccine|August 18, 2021
Vaccine market access pathways in the EU27 and the United Kingdom - analysis and recommendations for improvementsValérie Laigle, Maarten J Postma, Mira Pavlovic, et al.
Advances in Therapy|February 10, 2025
Cost-effectiveness Analysis of COVID-19 mRNA XBB.1.5 Fall 2023 Vaccination in the NetherlandsFlorian Zeevat, Simon van der Pol, Tjalke Westra, et al.
Pharmacogenetics and Genomics|August 22, 2009
Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphismStefan Vegter, Annalisa Perna, Wâtse Hiddema, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|October 8, 2009
Towards a healthier discount procedureRogier M Klock, Werner Bf Brouwer, Lieven Jp Annemans, et al.
Plos One|December 30, 2016
A Model Based Cost-Effectiveness Analysis of Routine Genotyping for CYP2D6 among Older, Depressed Inpatients Starting Nortriptyline PharmacotherapyElizabeth J J Berm, Judith J Gout-Zwart, Jos Luttjeboer, et al.
Vaccines|August 6, 2020
Pneumococcal Vaccination for Children in Asian Countries: A Systematic Review of Economic Evaluation StudiesNeily Zakiyah, Widya N Insani, Auliya A Suwantika, et al.
Pageof 49

Showing results (171-180 of 485) with videos related to

Sort By:
Pageof 49
Journal of Medical Economics|May 20, 2017
Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the NetherlandsMarieke Heisen, Maarten J Treur, Harald E Heemstra, et al.
Value in Health Regional Issues|February 24, 2018
Health-Related Quality of Life of Patients with HPV-Related Cancers in IndonesiaDidik Setiawan, Arrum Dusafitri, Githa Fungie Galistiani, et al.
Value in Health Regional Issues|January 9, 2024
Analysis of Health-Related Quality of Life and Incurred Costs Among Human Immunodeficiency Virus, Tuberculosis, and Tuberculosis/HIV Coinfected Outpatients in IndonesiaLusiana R Idrus, Najmiatul Fitria, Fredrick D Purba, et al.
Epidemiology (Cambridge, Mass.)|November 1, 2017
Estimating the Population-Level Effectiveness of Vaccination Programs in the NetherlandsMaarten van Wijhe, Scott A McDonald, Hester E de Melker, et al.
Vaccine|August 18, 2021
Vaccine market access pathways in the EU27 and the United Kingdom - analysis and recommendations for improvementsValérie Laigle, Maarten J Postma, Mira Pavlovic, et al.
Advances in Therapy|February 10, 2025
Cost-effectiveness Analysis of COVID-19 mRNA XBB.1.5 Fall 2023 Vaccination in the NetherlandsFlorian Zeevat, Simon van der Pol, Tjalke Westra, et al.
Pharmacogenetics and Genomics|August 22, 2009
Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphismStefan Vegter, Annalisa Perna, Wâtse Hiddema, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|October 8, 2009
Towards a healthier discount procedureRogier M Klock, Werner Bf Brouwer, Lieven Jp Annemans, et al.
Plos One|December 30, 2016
A Model Based Cost-Effectiveness Analysis of Routine Genotyping for CYP2D6 among Older, Depressed Inpatients Starting Nortriptyline PharmacotherapyElizabeth J J Berm, Judith J Gout-Zwart, Jos Luttjeboer, et al.
Vaccines|August 6, 2020
Pneumococcal Vaccination for Children in Asian Countries: A Systematic Review of Economic Evaluation StudiesNeily Zakiyah, Widya N Insani, Auliya A Suwantika, et al.
Pageof 49